Interpace biosciences, inc. (IDXG)
CashFlow / Quarterly
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash Flows From Operating Activities
Net loss

-10,726

-7,362

-5,220

-3,419

-4,037

-3,042

-1,917

-3,193

-5,008

-3,316

-6,306

2,414

6,281

-7,493

-2,334

-4,786

4,385

-4,895

-6,978

-3,868

-7,468

-4,335

-2,658

-1,612

-3,666

-2,141

-884

2,126

-23,796

-1,020

-439

-272

-10,266

-203

-895

-550

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

1,276

1,162

876

873

884

870

855

855

877

876

965

972

993

1,100

1,133

1,257

1,255

1,276

1,304

1,195

1,063

491

380

457

503

345

289

288

544

494

495

501

694

788

779

785

Realignment accrual accretion

-

-

-

-

-

-

-

-

-

-

-

-

5

6

7

16

35

34

35

35

36

35

36

35

36

35

36

35

36

35

36

35

-96

78

79

100

Gain on sale of discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Interest accretion

109

111

91

129

-

-

-

-

0

41

40

231

543

539

859

203

270

279

285

261

139

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Bad debt expense

-

-

-

-

-

-

-

-

41

-31

-9

34

417

313

80

89

600

30

76

96

0

0

0

0

-

-

-

-

-

-

-

-

47

8

-4

7

Amortization of debt issuance costs

-

-

-

-

-

-

-

-

0

0

96

21

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Mark to market on warrants

-244

10

-42

-3

-147

325

5

-71

-260

325

76

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Mark to market on derivatives

-

-

-

-

-

-

-

-

0

0

-19

-42

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on sale of discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

21,417

0

-68

285

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

289

256

452

538

706

524

443

597

583

271

148

58

22

21

21

67

2,500

463

658

396

360

406

668

690

204

446

722

351

271

484

607

429

253

424

532

727

Reversal of severance accrual

-

-

-

-

-

-

-

-

0

0

0

-2,034

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of debt

-

-

-

-

-

-

-

-

0

0

-2,731

-1,547

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent consideration

-

-

-

-

-

-

-

-

174

0

0

-5,776

-10,686

-1,174

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other gains and expenses, net

0

0

0

-18

-

-

-

-

-

-

-

-

0

0

-9

13

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other changes in operating assets and liabilities:
Increase in accounts receivable

-1,025

-1,996

2,244

1,738

843

993

1,244

466

640

76

422

90

-127

116

-485

-4,270

1,229

414

-1,386

5,229

2,441

-443

-4,625

6,049

-1,598

-2,074

-3,444

-1,140

2,422

-641

1,117

-1,844

-1,137

6,067

-10,951

4,624

Decrease in unbilled receivable

-

-

-

-

-

-

-

-

-

-

-

-

32

0

0

-16

883

-1,012

730

-420

1,644

-598

1,378

-2,424

1,337

-909

486

5,113

970

-1,230

-380

2

-345

960

-825

-560

Decrease (increase) in other current assets

-546

165

263

-11

327

134

120

-80

-60

-109

108

-161

-206

-1,413

-319

460

-1,266

-1,289

-233

438

-1,926

-1,247

-473

-32

590

-1,526

-474

-330

281

-1,069

1,094

452

1,263

232

750

-448

Increase in other long-term assets

-

-

-

-

-

-

-

-

0

0

30

-250

-2,250

-127

62

-689

-1,149

345

-326

-2,156

-202

147

2

-140

-165

0

0

0

1

1,024

-926

-92

-1,900

-721

9

-5

(Decrease) increase in accounts payable

-69

-1,296

437

93

-6

-108

438

344

-425

-850

-1,653

295

904

309

817

-1,887

819

158

1,316

-1,274

285

796

-438

143

582

-1,379

-931

690

234

-413

265

-837

1,748

-1,684

1,286

-477

(Decrease) in unearned contract revenue

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-11

-5,597

-1,758

-1,990

4,144

839

-240

-934

-594

-2,639

49

-1,906

-626

-1,749

-166

-139

673

-5,501

6,117

-1,029

2,878

Decrease in accrued salaries and bonus

-

-

-

-

-

-

-

-

-

-

-

-

48

-52

-261

-372

-1,260

-1,154

2,269

1,040

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase in accrued salaries and bonus

254

369

-466

325

278

208

-59

-397

410

-256

90

-1,639

-

-

-

-

-

-

-

-

-

556

-906

-2,480

-

-946

760

1,143

-

1,288

-672

-1,879

-

-457

-316

-438

Increase (decrease) in accrued liabilities

-

-

-

156

-

-

-

-292

-541

-1,421

-141

-648

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Decrease in accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-431

396

-2,391

-2,566

3,929

-1,334

-1,382

-4,602

994

756

-1,405

835

-185

117

-2,865

1,128

-2,100

1,266

-3,207

-1,872

5,854

2,887

-3,710

-3,214

Increase (decrease) in long-term liabilities

8

332

57

57

-264

66

67

49

329

-200

81

13

-1,771

-98

17

-482

-1,358

597

601

336

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase (decrease) in long-term liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-284

-286

-484

-

-233

-449

-270

-

-198

-532

-610

-

98

-514

-1,674

Net cash used in operating activities

-6,401

-4,771

-4,825

-2,960

-1,873

-1,773

-2,533

-2,494

-2,379

-4,312

-4,423

-4,149

-990

-1,346

-1,301

-3,970

-6,306

-5,396

-2,523

-5,617

-8,412

322

-1,825

-6,463

-3,749

811

-1,796

1,222

-7,131

3,686

-4,491

-2,350

-1,100

1,518

-188

1,755

Cash Flows From Investing Activity
Purchase of property and equipment

26

57

36

12

61

309

19

60

0

29

0

0

0

0

0

0

-230

41

78

464

1,553

438

346

514

170

692

511

445

584

80

438

10

9

85

377

-128

Sale of property and equipment

0

0

0

13

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loan to privately held non-controlled entity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,224

-569

-

0

0

0

-

-

-

-

-

-

-

-

Net cash used in investing activity

-26

-13,886

-36

1

-61

-309

-19

-60

0

-29

0

0

0

0

0

0

26,981

-41

-78

-464

-14,912

-8,938

-432

-1,083

-170

-2,192

-511

-445

-584

-80

-438

-10

-9

-85

-377

128

Cash Flows From Financing Activities
Issuance of common stock, net of expenses

516

0

-53

6,015

-

-

-

-

-961

1,779

11,562

10,701

1,707

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for repurchase of restricted shares

-

-

-

-

-

-

-

-

-

0

0

28

-

0

0

0

171

5

6

26

13

0

0

215

69

15

3

227

31

15

5

105

-

-

-

-

Cash paid for repurchase of restricted shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9

Payments for Repurchase of Common Stock

-

-

-

-

-

-

-

-

-

0

0

28

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

6,390

16,805

-53

6,015

-

-

-

-

5,875

1,779

11,562

10,673

-101

0

0

0

-21,320

-5

-6

-26

19,430

0

0

-215

-69

-15

-3

-227

-31

-15

-5

-105

-5

-2

0

-9

Net increase (decrease) in cash and cash equivalents

-

-

-

3,056

-

-

-

-2,554

3,496

-2,562

7,139

6,524

-1,091

-1,346

-1,301

-3,970

-645

-5,442

-2,607

-6,107

-3,894

-8,616

-2,257

-7,761

-3,988

-1,396

-2,310

550

-7,746

3,591

-4,934

-2,465

-1,114

1,431

-309

1,618

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

975

683

652

818

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-